Clinical Trials Logo

Coronary Artery Stenosis clinical trials

View clinical trials related to Coronary Artery Stenosis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06281041 Active, not recruiting - Clinical trials for Coronary Artery Disease

Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention

NHIS
Start date: January 1, 2013
Phase:
Study type: Observational

There is no specific recommendation regarding pharmacologic treatment as primary prevention for patients with intermediate coronary artery stenosis whose revascularization was deferred based on negative fractional flow reserve (FFR). Current nationwide cohort study conducted using Korean National Health Insurance Service database evaluated the safety and efficacy of antiplatelet therapy in patients with intermediate coronary artery stenosis with deferred revascularization based on negative FFR (FFR>0.80).

NCT ID: NCT04666584 Active, not recruiting - Clinical trials for Coronary Artery Disease

Optimal Predilatation Treatment Before Implantation of a Magmaris Bioresorbable Scaffold in Coronary Artery Stenosis

OPTIMIS
Start date: December 14, 2020
Phase: N/A
Study type: Interventional

The aim of the study is to investigate if lesion preparation with a ScoreFlex balloon compared to a standard non-compliant balloon improve vascular healing and minimize lumen reduction after implantation of a Magmaris bioresorbable scaffold.

NCT ID: NCT04192747 Active, not recruiting - Clinical trials for Coronary Artery Disease

The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries

BIOADAPTOR RCT
Start date: December 16, 2020
Phase: N/A
Study type: Interventional

The objective of this study is to verify the safety and efficacy of the investigational device (ELX1805J) for the treatment of ischemic heart disease due to de novo, native coronary artery lesions

NCT ID: NCT03185221 Active, not recruiting - Clinical trials for Coronary Artery Stenosis

Cordimax China Post Market Surveillance

Start date: June 20, 2013
Phase: Phase 3
Study type: Interventional

Study purpose: This study is a prospective, randomized, controlled multicenter clinical research, which is to assess the effect of Cordimax and Xience V drug-eluting stents as they dealing with all kinds of complex lesions in the real world. Study group Experimental group: Cordimax® Rapamycin Eluting Coronary Stent System Control group: XIENCE V® Everolimus Eluting Coronary Stent System

NCT ID: NCT01960504 Active, not recruiting - Clinical trials for Coronary Artery Disease

First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)

BIOSOLVE-II
Start date: October 2013
Phase: N/A
Study type: Interventional

BIOSOLVE-II is a prospective, international, multicenter, First in Man study. The purpose of this study is to assess the safety and clinical performance of the drug eluting absorbable metal scaffold (DREAMS 2nd Generation).

NCT ID: NCT01342822 Active, not recruiting - Clinical trials for Ischemic Heart Disease

Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization

PLATINUM+
Start date: October 2010
Phase: Phase 4
Study type: Observational

The PROMUS Element™ clinical trial (PLATINUM-PLUS) consists of a randomized controlled trial (RCT) in the European Union (EU) which will enroll approximately 2980 subjects (2:1 randomization PROMUS Element™: Xience™ Prime) in a Population of consecutive, all comers in the reimbursed indications per-country All subjects will be screened per the protocol required inclusion/exclusion criteria.